Novel Drug Delivery Systems (NDDS) News

Recent industry report about Novel Drug Delivery Systems (NDDS) company news, including latest market trends and industry updates in 2024. This sector news is compiled by Mordor Intelligence™ Novel Drug Delivery Systems (NDDS) Market industry experts.

Novel Drug Delivery Systems (NDDS) News

  • June 2022: Esteve Pharmaceuticals GmbH launched INBRIJA 33 mg (levodopa inhalation powder, hard capsules) in Germany. INBRIJA is indicated in the EU for the intermittent treatment of episodic motor fluctuations in adult patients with Parkinson's disease treated with a levodopa/dopa-decarboxylase inhibitor.
  • June 2022: EVERSANA and Accord BioPharma partnered to support the recent launch of CAMCEVI (leuprolide) 42mg injection emulsion for treating advanced prostate cancer in adults.
Get full market coverage in this industry
Download PDF
  • August 2024: SMT (Sahajanand Medical Technologies) successfully completed patient enrolment for the Tuxedo 2 clinical trial in India. This pivotal trial seeks to assess the efficacy and safety of the Supraflex Cruz Drug-Eluting Stent (DES) specifically in diabetic patients suffering from multivessel coronary artery disease (CAD).
  • May 2024: Abbott launched its XIENCE Sierra Everolimus Eluting Coronary Stent System in India. As a cutting-edge addition to the XIENCE family, the XIENCE Sierra stent caters to individuals grappling with blocked coronary arteries.
  • May 2024: WHO supported the procurement of diagnostic products and related laboratory items for the diagnosis and management of many communicable and non-communicable diseases including Dengue infections.
  • October 2023: UNICEF delivered dengue testing kits to hospitals across Bangladesh, including Shaheed Ahsan Ullah Master General Hospital, through the Centre for Disease Control (CDC) under the Directorate General of Health Services.
  • May 2024: Bruker Corporation completed the acquisition of ELITechGroup a differentiated and profitable provider of systems and assays for molecular diagnostics (MDx), biomedical systems/specialty IVD, and microbiology.
  • January 2024: ELITechGroup launched its in-vitro diagnostic kit, gastrointestinal (GI) Bacterial PLUS ELITe MGB kit, which received the Conformite Europeenne In Vitro Diagnostic Devices Regulation (CE-IVDR) certification. This kit is used to combat bacterial pathogens, including Campylobacter spp., Clostridium difficile, Salmonella spp., and others.
  • September 2024: Clinic Sese Clinches the Title of Best Regenerative Aesthetics Clinic in the United Kingdom for 2024. The recognition is rooted from the treatment offerings towards the advanced anti-aging aesthetics, wellness, weight loss, and women's health.
  • September 2023: The United Kingdom government initiated a consultation to examine ways to enhance the safety of Botox and other non-surgical cosmetic treatments. The consultation lasted for 8 weeks. This initiative comes in the wake of the Health and Care Act's passage in April 2022, which empowered the Health and Social Care Secretary to establish a licensing regime.
  • March 2024: Stryker Corporation introduced a novel, innovative product, LIFEPAK CR2 automated external defibrillator (AED), to improve cardiac care and enhance patient outcomes.
  • January 2024: Accelus launched a linesider modular-cortical system that can be used for spinal implant surgeries. This implant is expected to be used by the surgeons to support the spine during surgeries.
  • In July 2024, NxGen MDx unveiled its groundbreaking Early Advantage Panel (EAP) and Super Panel. These state-of-the-art genetic carrier screens aim to deliver equitable screening solutions, guaranteeing thorough and precise outcomes for all individuals, irrespective of their ethnic background.
  • In June 2024, Myriad Genetics, Inc. unveiled its new Universal Plus Panel as part of the Foresight Carrier Screen. This panel encompasses 39 conditions and evaluates up to 272 genes linked to severe inherited disorders.
  • In April 2024, GC Aesthetics introduced the LUNA XT, a micro-textured anatomical breast implant, marking one of the pioneering European Medical Device Regulation (MDR)-approved products in its category.
  • In September 2023, Queen's University Belfast professionals reported developing 4D-printed smart implants tailored for breast cancer patients. These implants are designed to adjust their size to fit perfectly within the individual's breast cavity, resulting in better aesthetic outcomes and an increase in confidence for those who have previously undergone breast cancer treatment. Additionally, these implants can dispense chemotherapy drugs, protecting against cancer cell recurrence in the treated area.
  • January 2024: Clarius Mobile Health, a global leader in wireless ultrasound solutions, received 510(k) clearance from the United States Food and Drug Administration (FDA) for its new Clarius Bladder AI, a non-invasive tool that automatically measures bladder volume in seconds. It was made available in the United States with the Clarius PAL HD3, Clarius PA HD3, and the Clarius C3 HD3 wireless handheld ultrasound bladder scanners.
  • April 2023: The University of Arkansas for Medical Sciences (UAMS) opened a new Urology Center in Premier Medical Plaza in West Little Rock, United States. The new Urology Center offers specialized treatment for complex kidney stones, reconstruction of the urinary system, and men's health, specifically erectile dysfunction, along with top-quality routine urology services, including bladder scanning.
  • February 2024: CMR Surgical introduced a vLimeLite fluorescence imaging system to help surgeons visually assess the blood vessels and blood flow, facilitating surgical procedures.
  • February 2024: PENTAX Medical received its CE mark for the i20c video endoscope series -video colonoscope EC34-i20c, video upper GI scope EG27-i20c, and R/L knob adaptor OE-B17, which can support healthcare professionals in improving detection, diagnosis, and treatment, as well as enhance patient outcomes.
  • April 2024 Bio-Rad Laboratories Inc. launched its ultrasensitive multiplexed digital PCR assay, the ddPLEX ESR1 Mutation Detection Kit. The assay helped expand the company’s Droplet Digital PCR offering for the oncology market, where highly sensitive and multiplexed mutation detection assays aid translational research, therapy selection, and disease monitoring.
  • January 2024: ELITechGroup launched its CE-IVDR-certified GI Bacterial PLUS ELITe MGB Kit and expanded its in vitro diagnostic portfolio. The kit is tailored specifically for diagnosing gastrointestinal bacterial infections. The in vitro assay exclusively targets major bacterial pathogens.

NDDS Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)